核苷和核苷酸类药物治疗对慢性乙型肝炎患者生活质量的影响

钟春秀; 蔡少航; 尹军花; 高钰琳

doi:10.3969/j.issn.1001-5256.2016.11.013

核苷和核苷酸类药物治疗对慢性乙型肝炎患者生活质量的影响

DOI: 10.3969/j.issn.1001-5256.2016.11.013

1. 南方医科大学南方医院感染内科
2. 南方医科大学护理学院

基金项目:

广东省医学科学技术研究基金(A2014413)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 1866
- HTML全文浏览量: 10
- PDF下载量: 458
- 被引次数: 0
出版历程
- 出版日期: 2016-11-20

Impact of nucleos(t)ide analogues on quality of life in patients with chronic hepatitis B

Research funding:

摘要

摘要:
目的分析核苷和核苷酸类药物治疗对慢性乙型肝炎（CHB）患者生活质量的影响,并探讨相应护理措施。方法选取2010年3月-2014年7月于南方医科大学南方医院感染内科临床研究的102例CHB患者,分为持续治疗组（n=54）与停药组（n=48）,以SF-36表测量生活质量。治疗组于治疗前与治疗96周接受评估,停药组于停药点与停药48周接受评估。计量资料组间比较采用t检验,组内比较采用配对t检验;计数资料组间比较采用χ2检验。单因素及多因素分析采用Logistics回归分析。结果与抗病毒前比较,持续治疗组患者抗病毒治疗96周后,其生理功能、生理职能、躯体疼痛、总体健康均明显升高（94.91±7.11 vs 92.13±10.58,81.94±24.96 vs 71.76±34.01,87.72±8.64 vs 82.85±12.88,59.63±14.59 vs 53.52±16.79,t=-3.786-2.623,P值均<0.05）。但心理质量除精神健康由67.30±18.94提高至75.56±15.53（t=-3.883,P<0.001）外,其余维度均无明...
- 肝炎,乙型,慢性 /
- 核苷类 /
- 核苷酸类 /
- 生活质量 /
- 精神卫生
Abstract:
Objective To investigate the impact of treatment with nucleos( t) ide analogues on quality of life( Qo L) in patients with chronic hepatitis B( CHB),as well as proper nursing measures. Methods A total of 102 CHB patients who were treated in Department of Infectious Diseases,Nanfang Hospital,Southern Medical University from March 2010 to July 2014 were enrolled and divided into continuous treatment group( 54 patients) and drug withdrawal group( 48 patients). The 36- item short- form health survey( SF- 36) was used to measure Qo L. The patients in the treatment group were evaluated before treatment and at 96 weeks of treatment,and those in the drug withdrawal group were evaluated at the time of drug withdrawal and at 48 weeks after drug withdrawal. The t- test was used for comparison of continuous data between groups,and the chi- square test was used for comparison of categorical data between groups. The logistic regression analysis was performed for univariate and multivariate analyses. Results Compared with before treatment,the continuous treatment group had significant increases in the scores on the domains of physiological function,role physical,bodily pain,and general health after 96 weeks of antiviral therapy( physiological function: 94. 91 ± 7. 11 vs 92. 13 ± 10. 58,t =- 2. 924,P < 0. 05; role physical: 81. 94 ± 24. 96 vs71. 76 ± 34. 01,t =- 2. 623,P < 0. 05; bodily pain: 87. 72 ± 8. 64 vs 82. 85 ± 12. 88,t =- 3. 576,P < 0. 05; general health: 59. 63 ±14. 59 vs 53. 52 ± 16. 79,t =- 3. 786,P < 0. 05). As for psychological quality,the continuous treatment group had a significant increase in the subscale of mental health( 67. 30 ± 18. 94 vs 75. 56 ± 15. 53,t =- 3. 883,P < 0. 001),while there were no significant improvements in other subscales. At 48 weeks after drug withdrawal,the drug withdrawal group had significant increases in role physical( 84. 20 ± 18. 97 vs72. 49 ± 24. 38,t =- 2. 768,P < 0. 05),general health( 69. 28 ± 22. 94 vs 56. 41 ± 18. 27,t =- 3. 206,P < 0. 05),and mental health( 75. 02 ± 16. 03 vs68. 94 ± 14. 07,t =- 2. 078,P < 0. 05). The multivariate analysis showed that marital status was associated with the improvement in QoL after antiviral therapy( odds ratio = 11. 61,95% CI: 2. 28- 59. 00,P = 0. 003); the unmarried patients had better improvements in Qo L compared with the married ones,especially physiological function( t =- 2. 176,P = 0. 034),role physical( t =- 2. 173,P = 0. 034),and role emotional( t =- 2. 811,P = 0. 007). Conclusion Antiviral therapy can improve the Qo L and mental health of CHB patients. Effective psychological intervention is necessary for CHB patients,especially married CHB patients.
- hepatitis B,chronic /
- nucleosides /
- nucletides /
- quality of life /
- mental health

HTML全文

参考文献(14)

[1]European Association for the Study of the Liver.EASL clinical practice guidelines:management of chronic hepatitis B virus infection[J].J Hepatol,2012,57(1):167-185.

[2]WU X,CAI S,LI Z,et al.Potential effects of telbivudine and entecavir on renal function:a systematic review and metaanalysis[J].Virol J,2016,13:64.

[3]HE JN,LI NH,ZHANG Y,et al.An analysis of medical reform in the US and countermeasures for aging in the world[J].Chin J Gerontol,2012,32(2):421-424.(in Chinese)何靖楠,李宁华,张毅,等.美国医改及世界应对老龄化对策分析[J].中国老年学杂志,2012,32(2):421-424.

[4]BEUTELS P,MUSABAEV EI,van DAMME P.The disease burden of hepatitis B in uzbekistan[J].J Infect,2000,40(3):234-241.

[5]YIN JH,CAI SH,ZHONG CX,et al.Suvey of psychological stress in chronic hepatitis B patients in different population[J].Chin Nurs Res,2014,28(6):669-671.(in Chinese)尹军花,蔡少航,钟春秀,等.不同人群慢性乙型肝炎病人心理压力的调查[J].护理研究,2014,28(6):669-671.

[6] Chinese Society of Hepatology,Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2010年版)[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.

[7]CHANG SC,YANG SS,CHANG CC,et al.Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ[J].Health Qual Life Outcomes,2014,12:97.

[8]THEIN HH,KRAHN M,KALDOR JM,et al.Estimation of utilities for chronic hepatitis C from SF-36 scores[J].Am J Gastroenterol,2005,100(3):643-651.

[9]MODABBERNIA A,ASHRAFI M,MALEKZADEH R,et al.A review of psychosocial issues in patients with chronic hepatitis B[J].Arch Iran Med,2013,16(2):114-122.

[10]KALLMAN J,O'NEIL MM,LARIVE B,et al.Fatigue and healthrelated quality of life(HRQL)in chronic hepatitis C virus infection[J].Dig Dis Sci,2007,52(10):2531-2539.

[11]PENG J,YIN J,CAI S,et al.Factors associated with adherence to nucleos(t)ide analogs in chronic hepatitis B patients:results from a 1-year follow-up study[J].Patient Prefer Adherence,2015,9:41-45.

[12]ZHANG Y,ZHOU JJ,WANG YM.Effects of psychotherapy on depression and anxiety of patients with chronic hepatitis B:a meta-analysis[J].World Chin J Dig,2008,16(1):101-104.(in Chinese)张耀,周吉军,王宇明.心理干预对国内慢性乙型肝炎患者焦虑抑郁情绪影响的荟萃分析[J].世界华人消化杂志,2008,16(1):101-104.

[13]FUNG J,LAI CL,TANAKA Y,et al.The duration of lamivudine therapy for chronic hepatitis B:cessation vs.continuation of treatment after HBeA g seroconversion[J].Am J Gastroenterol,2009,104(8):1940-1946,1947.

[14]KESKIN G,GUMUS AB,ORGUN F.Quality of life,depression,and anxiety among hepatitis B patients[J].Gastroenterol Nurs,2013,36(5):346-356.

施引文献

资源附件(0)

访问统计